QurAlis key facts
as of Oct 2026- Developer of precision therapeutics and tools designed for amyotrophic lateral sclerosis and other neurodegenerative diseases with genetically validated targets.
- QurAlis is valued at approximately $178.0M as of Oct 2026 (last reported valuation).
- It has raised $158.4M across 4 recorded rounds; the latest was Early Stage VC ($20.0M) in Aug 2025.
- Notable investors include Alexandria Venture Investments, Johnson & Johnson Innovation - JLABS, Polaris Partners, Dolby Family Ventures, SV Health Investors — 21 tracked in total.
- QurAlis has filed 4 Form Ds with the SEC since 2020, most recently Sep 2025 ($20.0M sold to 19 investors).
- Status: Privately Held (backing).
QurAlis's last reported valuation, Mar 2023. Nothing priced has surfaced since.
- ·The complete investor list: 21 names
- ·Watch QurAlis: the Monday email on marks, rounds and moves
QurAlis funding rounds
4 roundsWho backs QurAlis
21+QurAlis valuation
QurAlis's last reported valuation was $178 million in Mar 2023. No priced round, secondary trade or fund mark has surfaced since.
How much has QurAlis raised?
QurAlis has raised $158 million across 4 recorded rounds since 2020. The largest was a $60 million later-stage round in Dec 2022; the most recent was a $20 million early-stage round in Aug 2025.
QurAlis has filed 4 Form Ds with the SEC since 2020, most recently in Sep 2025 ($20 million sold to 19 investors).
QurAlis investors
21 investors are on record for QurAlis, including Alexandria Venture Investments, Johnson & Johnson Innovation - JLABS, Polaris Partners and Dolby Family Ventures. By type, the record holds 5 venture capital firms and 1 family office. The early-stage round in Aug 2025 drew 19 investors.
About QurAlis
Developer of precision therapeutics and tools designed for amyotrophic lateral sclerosis and other neurodegenerative diseases with genetically validated targets. The company's proprietary platforms and biomarkers offer the design and development of drugs that act directly on disease-causing genetic alterations, advancing a robust precision medicine pipeline with therapeutic candidates that modify severe disease pathology in defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarker, enabling medical professionals to halt disease progression and significantly improve outcomes.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2016
- Employees
- 88
- Website
- quralis.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.